Imagine a lab the size of a smartphone, capable of detecting bioweapons in the field or diagnosing sepsis in a clinic. That’s the promise of Biomeme, a company quietly building a $13.5M business on the frontier of mobile molecular diagnostics. They aren't chasing consumer hype; they are arming military units and clinicians with the power of PCR.

"Biomeme isn't selling gadgets; they are shrinking the laboratory into a deployable asset."

The company's leadership team reflects this deep technical focus. With CEO Max Perelman at the helm and a biology lead as co-founder, the executive bench is rounded out by specialists in clinical quality and federal programs. This isn't a consumer app; it's a regulated medical device company navigating the FDA and DoD simultaneously.

• The 'biomme' typo captures 1,510 monthly searches, suggesting high brand recall (and likely confusion) among a niche audience.
• They rank for high-intent keywords like 'antimicrobial stewardship' (4,110 volume), targeting hospital decision-makers.
• Their tech stack (OpenCart, Magento, Shopware) suggests a complex e-commerce backend for handling enterprise orders.